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Summary: The mechanisms underlying secondary cell death
after traumatic brain injury (TBI) are poorly understood. Ani-
mal models of TBI recapitulate many clinical and pathologic
aspects of human head injury, and the development of geneti-
cally engineered animals has offered the opportunity to inves-
tigate the specific molecular and cellular mechanisms associ-
ated with cell dysfunction and death after TBI, allowing for the
evaluation of specific cause-effect relations and mechanistic
hypotheses. This article represents a compendium of the current
literature using genetically engineered mice in studies designed
to better understand the posttraumatic inflammatory response,
the mechanisms underlying DNA damage, repair, and cell
death, and the link between TBI and neurodegenerative dis-
eases. Key Words: Cell death—Head injury—Inflammation—
Neurodegeneration—Pathophysiology—Secondary brain dam-
age—Transgenic mice.
Traumatic brain injury (TBI) is a major cause of mor-
tality and disability in Europe and the United States, with
more than 2.5 million individuals in the U.S. alone living
with the devastating emotional and economic costs (NIH
Consensus Development Panel on Rehabilitation of Per-
sons With Traumatic Brain Injury, 1999). During the
past decade, the elucidation of “primary” (mechanical)
injury and “secondary” insults after head injury, im-
provement in pre-hospital care, classification of injury
severity, refinement of radiologic imaging, prompt
evacuation of surgical masses, and advances in critical
care and rehabilitation have led to a proficient level of
care that has been summarized in guidelines for the ad-
vanced treatment of head-injured patients (The Brain
Trauma Foundation, 2000). Despite these advances,
many head-injured patients die or survive with signifi-
cant brain damage and behavioral impairment, even after
mild or moderate head injury (Jennett, 1997; Graham et
al., 2000a). Currently, no treatment is available to re-
verse the pathogenic cellular cascade underlying pro-
gression of cell death. A better understanding of the mo-
lecular and cellular mechanisms leading to posttraumatic
cell death and their relation to behavioral impairment
remains an important goal of experimental TBI research.
The pathobiologic processes that occur after brain in-
jury are known to be associated with primary injury
(caused by physical or biomechanical effects of trauma)
and secondary or delayed events initiated minutes after
trauma and lasting for weeks, months, or possibly years.
These pathologic injury cascades are believed to be as-
sociated with alterations in gene expression and the up-
regulation and release of a number of potentially dam-
aging or restorative neurochemical factors that interact in
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a complex network leading to delayed cellular dysfunc-
tion, death, or both. The extended nature of these cas-
cades offers the possibility for therapeutic interventions
(alone or in combination) aimed at blocking degenera-
tion or improving repair and regeneration (McIntosh et
al., 1998; Graham et al., 2000a).
Animal models of TBI have been developed to reca-
pitulate many clinical and pathologic aspects of head
injury and have provided the basis for the dramatic in-
crease in the understanding of the pathophysiology of
brain damage after trauma (Povlishock et al., 1994; Lau-
rer and McIntosh, 1999). Experimental models of TBI
typically use rodents because of the many advantages—
including small size, low cost, and the extensive amount
of normative data available (Povlishock et al., 1994).
Clinically relevant rodent models of TBI represent a re-
liable means to permit the use of sophisticated neuro-
chemical, histopathologic, and molecular techniques, and
genomic manipulation to help clarify the pathogenic
mechanisms underlying trauma-associated cell death.
Properties of genetically engineered animals and
rationale for their use
The use of genetically engineered mice typically in-
volves the artificial overexpression or targeted deletion
(knockout) of a specific gene. The development of this
technology has revolutionized the investigation of the
specific molecular and cellular mechanisms associated
with cell dysfunction and death after TBI. Currently,
mice are the preferred species for these studies because
the murine genome has been extensively mapped and is
suitable for embryonic cell technology. Different ap-
proaches with genetically engineered animals include
studies of naturally occurring genetic variability or mu-
tations and the creation of animals with targeted gene
deletions or with newly introduced transgenes (Steward
et al., 1999). This article summarizes the significant post-
traumatic pathways investigated to date using genetically
engineered mice, including inflammation and cytokines,
nitric oxide and oxidative damage, and DNA damage/re-
pair and apoptosis. In addition, we will overview the
studies that have been performed using transgenic mouse
technology to understand the epidemiologic link between
TBI and neurodegenerative diseases.
INFLAMMATION AND CYTOKINES
Traumatic brain injury results in an acute blood–brain
barrier (BBB) opening that allows the entry of leuko-
cytes into the injured brain (Holmin et al., 1995; Soares
et al., 1995). These cells (neutrophils and activated mac-
rophages) may release oxygen free radicals causing cel-
lular damage and inflammatory cytokines that have been
implicated in posttraumatic neuropathologic damage.
Posttraumatic inflammation also is associated with an
increase in expression of intercellular adhesion mol-
ecules (ICAM) such as ICAM-1, which is involved in
vascular adhesion, transendothelial migration of leuko-
cytes, and the release of cytokines such as tumor necrosis
factor- (TNF-), various interleukins, and various tro-
phic factors (Morganti-Kossman et al., 1997). Initially,
the mediators and cytokines involved in this cascade
were considered to be pathogenic factors. However, it is
now clear that posttraumatic inflammation also may con-
tribute to reparative and regenerative processes after TBI
(McIntosh et al., 1998; Shohami et al., 1999; Lenzlinger
et al., 2001). Macrophage activation results in removal of
dead tissue and debris by phagocytosis, lipid recycling,
and secretion of the above-mentioned spectrum of cyto-
kines possessing trophic, mitogenic, and chemotactic
properties that may contribute to healing, plasticity, and
regeneration (Lotan and Schwartz, 1994).
Intercellular adhesion molecules
Intercellular adhesion molecule-1 is a member of the
immunoglobulin family that is responsible for the re-
cruitment of leukocytes to inflammatory foci. The in-
crease in expression of ICAM-1 reported after clinical
and experimental brain trauma has been hypothesized to
be involved in secondary inflammatory damage (Carlos
et al., 1997; Whalen et al., 1997, 1998). Intercellular
adhesion molecule-1 knockout mice have been generated
by disruption of the fifth exon of the ICAM-1 locus in
129/Sv embryonic stem (ES) cells (Sligh et al., 1993).
These mice do not demonstrate any susceptibility to in-
fection, but do exhibit prominent abnormalities of the
peripheral inflammatory response, including impaired
neutrophil migration in response to chemical peritonitis
(Sligh et al., 1993).
Platelet (P)-selectin, a member of the selectin family,
mediates platelet and leukocyte rolling on endothelium
and platelet–neutrophil adhesion. Generation of P-
selectin knockout mice is obtained through the deletion
of exons 3–5. Although dual ICAM-1 and P-selectin
(−/−) mice completely lack neutrophil migration during
peritoneal inflammation, they develop normally, are fer-
tile, and appear to be healthy (Bullard et al., 1995). To
clarify the role of ICAM-1 and P-selectin after TBI,
ICAM-1 (−/−) and dual ICAM-1 and P-selectin (−/−)
mice were subjected to controlled cortical impact (CCI)
brain injury and were compared with wild type (WT)
mice. Surprisingly, these studies failed to reveal any dif-
ferences in brain neutrophil accumulation at 24 hours
postinjury, memory and motor function, or contusion
volume at 3 weeks after injury (Whalen et al., 1999a,
2000). These data suggest that after TBI, brain neutrophil
accumulation may be stimulus-specific and not depen-
dent on ICAM-1, or that these knockout mice may de-
velop a compensatory adhesion pathway. Further studies
are warranted to understand the difference between re-
sults obtained with genetically engineered mice and
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pharmacologic agents such as antibodies directed to
ICAM-1 that reduce by almost 40% the invasion of neu-
trophils into the injured brain during the first 24 hours
after injury (Carlos et al., 1997). However, brain edema
was observed to be decreased at 24 hours after TBI in
dual P-selectin and ICAM-1 (−/−) mice, suggesting a
possible role for adhesion molecules (particularly P-
selectin) in the pathogenesis of acute brain edema inde-
pendent of leukocyte accumulation (Whalen et al., 2000).
Because posttraumatic brain edema may be responsible
for a considerable increase in brain volume and intracra-
nial pressure, this pathway may be an important thera-
peutic target in clinical head injury. Additional studies
are needed to further define the role of ICAM-1 and
P-selectin in posttraumatic brain edema.
Tumor necrosis factor-
Brain injury induces a dramatic increase in the expres-
sion of TNF- but the exact role of this cytokine in
mediating posttraumatic damage is unclear (Shohami et
al., 1994; Fan et al., 1996). Tumor necrosis factor-
binds two different receptors (TNFR): p75 and p55. Ac-
tivation of the p55 receptor results in activation of the
nuclear factor B, which induces genes for manganese
superoxide dismutase (MnSOD) and calbindin (Das et
al., 1995; Mattson et al., 1995).
To understand the role of TNF in the postinjury cas-
cade, TNF (−/−) mice were generated using a replace-
ment-type targeting vector containing a phosphoglycer-
ate kinase (PGK)-neomycin (neo) expression cassette to
replace the TNF gene. Scherbel et al. (1999) subjected
TNF (−/−) mice and their WT littermates to CCI brain
injury of mild severity and observed that the brain-
injured TNF (−/−) mice exhibited attenuated cognitive
deficits and motor dysfunction during the first week after
injury when compared with WT littermates. However,
WT mice subjected to mild TBI showed a marked re-
covery with time, whereas TNF (−/−) mice displayed
persistent motor deficits up to 4 weeks after injury (Fig.
1). A significantly larger injury cavity also was observed
in TNF (−/−) mice at 2 and 4 weeks after injury, sug-
gesting that although this cytokine may play a deleteri-
ous role during the acute postinjury period, it may have
a beneficial role in long-term behavioral recovery and
tissue repair in the more chronic period after brain injury.
These data are partially in agreement with the results
obtained using pharmacologic agents aimed to reduce
TNF production, such as pentoxifylline and the synthetic
cannabinoid Dexanabinol (Jackson Laboratory, Bar Har-
bor, ME, U.S.A.), or its activity, such as TNF-binding
protein, suggesting that TNF antagonism in the acute
postinjury phase may be therapeutic (Shohami et al.,
1996, 1997b).
Because the lymphotoxin (LT) may compensate for
the absence of TNF by acting on the same receptors,
TNF/LT double-deficient mice have been produced by
inactivating both genes. These animals show splenic mi-
croarchitecture disorganization, immunoglobulin reduc-
tion, and impaired B and T cell function (Eugster et al.,
1996). When TNF/LT (−/−) mice were subjected to a
weight drop brain injury and were compared with brain-
injured WT mice, no differences were observed in neu-
rologic motor function (during the first 7 days), BBB
permeability at 4 hours after injury, neutrophil infiltra-
tion at 24 hours after injury, or cell death. However,
TNF/LT (−/−) mice have been reported to show an in-
creased mortality at 1 week after injury, suggesting a
protective role for these cytokines (Stahel et al., 2000).
Although these data differ from those obtained from Sch-
erbel et al. (1999), in which the deletion of TNF gene was
suggestive of an acute detrimental effect of TNF, these
differences may be caused by the effects of deletion of
different genes and the use of different strains of mice
and models of central nervous system (CNS) injury.
In addition to the deletion of the TNF gene, mice lack-
ing either p75 or p55 receptors have been generated by
the disruption of the TNFR genes and replacement with
a neomycin (neo) resistance gene. Homozygous p75 and
p55 knockout mice were subsequently mated to obtain
mice that are deficient in both receptors. These knockout
mice show altered response of lymphocytes to infectious
agents (Zheng et al., 1995; Bruce et al., 1996), but re-
produce normally, appear to be healthy, and fail to show
any behavioral deficits or overt brain structural alter-
ations compared with naïve WT littermates. After CCI
brain injury, TNFR knockout mice, lacking p75 and p55
receptors, showed a greater lesion volume (7 days after
injury) and alteration in BBB permeability, delayed NF-
B activation, and reduced MnSOD expression in the
acute posttraumatic period compared with WT litter-
mates (Sullivan et al., 1999). Moreover, because Mn-
SOD overexpressing mice showed a reduced posttrau-
FIG. 1. Comparison of posttraumatic recovery of neurologic mo-
tor function evaluated by composite neuroscore in tumor necrosis
factor (TNF) (−/−) mice and their wild type (WT) littermates after
controlled cortical impact brain injury. Reprinted with permission
from Scherbel et al., 1999. Copyright ©1999 National Academy of
Sciences, U.S.A.
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matic lesion volume at 7 days compared with WT con-
trols, it was suggested that TNFR-mediated NF-B
activation may initiate neuroprotective pathways early in
the postinjury cascade through MnSOD induction, which
exerts antioxidative and antiapoptotic activity (Sullivan
et al., 1999). The results obtained using TNFR (−/−)
mice suggest that TNF may be neuroprotective even in
the acute posttraumatic period, creating a more complex
picture of the role of this cytokine in TBI. Taken to-
gether, these studies prompt the reevaluation of thera-
peutic strategies aimed at suppressing TNF- production
or blocking its activity and serve as a reminder that the
timing of manipulation of specific cellular and molecular
pathways through pharmacologic intervention is critical.
Interleukins and metallothioneins
Interleukin-1 converting enzyme (ICE or caspase-1)
was the first identified member of the caspase family
responsible for cleavage of pro–IL-1 into biologically
active IL-1 that may play a role during cell death.
Transgenic mice expressing a dominant negative inhibi-
tor of caspase-1 have been generated by inserting cyste-
ine in substitution for glycine at the active site
(ICEC285G), under the control of a neuron-specific eno-
lase promoter (NSE-M17Z). The embryonic develop-
ment of these TG mice is normal, and although they
appear neurologically normal postnatally, dorsal root
ganglial neurons isolated from this strain are resistant to
trophic factor withdrawal-induced apoptosis (Friedlander
et al., 1997). Moreover, the neurons isolated from new-
born caspase-1 knockout mice are similarly resistant to
trophic factor withdrawal-induced apoptosis (Friedlander
et al., 1997). Transgenic mice expressing the mutant
gene of caspase-1 (ICEC285G) when subjected to CCI
brain injury showed lower levels of caspase-1, reduced
motor deficits, and smaller lesion volume compared with
brain-injured WT mice. This neuroprotection was asso-
ciated with a decrease in oxygen free radical release and
was replicated by pharmacologic inhibition of caspase-1
using the selective peptide inhibitor AcYVAD-cmk and
the nonselective pan-caspase inhibitor zVAD-fmk (Fink
et al., 1999).
Interleukin-6 is a proinflammatory cytokine, known to
protect cultured mesencephalic, catecholaminergic, and
septal neurons from the toxic effect of glutamate (Hama
et al., 1991; Toulmond et al., 1992). Interleukin-6 mRNA
expression and protein levels are increased in the rat
brain after a weight drop TBI and in cerebrospinal fluid
after human head injury (Kossmann et al., 1996; Hans et
al., 1999). Moreover, IL-6 induces expression of acute-
phase proteins called metallothioneins (MT), which may
have antioxidant properties and may regulate zinc and
copper metabolism. These proteins also modulate cat-
echolaminergic, glutamatergic, and GABAergic trans-
mission, and their expression is altered in different
pathophysiologic conditions, including neurodegenera-
tive diseases and cortical freeze injury (Penkowa and
Moos, 1995; Aschner et al., 1997).
Generation of IL-6–deficient mice has been achieved
by the disruption of the IL-6 gene in 129 Sv ES cells by
the insertion of neomycin into the first coding exon of
IL-6. Homozygous IL-6 knockout mice develop nor-
mally, but show a compromised inflammatory acute-
phase response after tissue damage (Kopf et al., 1994).
After cortical freeze injury in IL-6 (−/−) knockout mice,
the number of activated glial cells and brain macro-
phages was reduced by 3 days after injury. A reduction in
MT isoforms I and II and an increase of isoform III
expression with a greater neuronal cell loss in the fronto-
parietal cortex was observed compared with WT litter-
mates (Penkowa et al., 1999b). These authors suggested
that IL-6 is essential for activation of microglia and re-
cruitment of monocytes and astrocytes after brain injury
(Penkowa et al., 1999b).
Metallothionein production is induced by IL-6, and to
understand the role of these proteins in the response to
CNS injury, MT I and II knockout mice have been gen-
erated, inactivating the genes by homologous recombi-
nation using clones lacking in MT I and II alleles. Naïve
metallothionein-deficient mice do not show any ana-
tomic or histologic difference when compared with their
WT littermates (Penkowa et al., 1999a). In a model of
cortical freeze injury, MT I–II knockout mice, compared
with WT-injured mice, showed a more pronounced in-
filtration of microglia and macrophages, a prolonged,
abnormal inflammatory response up to 90 days, an in-
crease in neuronal cell loss and apoptosis, and a reduc-
tion in wound healing and tissue regeneration due to
altered angiogenesis (Penkowa et al., 1999a, 2000).
These studies suggest that these proteins may be impor-
tant for the proper control of the inflammatory response,
oxidative homeostasis, and apoptosis (caused by greater
oxidative stress and alterations in zinc concentration) af-
ter brain injury.
Astrocytes and tissue repair
Astrocytes play an important role in maintaining meta-
bolic homeostasis in the CNS. The biologic significance
of reactive astrocytosis after TBI is of great interest be-
cause this can lead to a glial scar formation, which may
putatively impede CNS regeneration, or to the release of
trophic factors that support regeneration. Steward and
Trimmer (1997), using a substrain of C57BL/6 mice that
contains the Ola mutation and is characterized by mark-
edly delayed Wallerian degeneration (Wlds), studied as-
trocyte activation in a model of denervation and showed
that reactive changes in astrocytes are triggered by fac-
tors released by activated microglia. The delayed glial
response to injury is believed to have detrimental con-
sequences, including the inhibition of regeneration of the
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injured neurons. Fox and Faden (1998) compared the
temporal course of the behavioral alterations caused by
CCI brain injury in C57BL/6 and C57BL/6/Wlds mice
and showed that behavioral impairment is delayed in
Wlds mice. To further clarify the role of astrocytes after
CNS injury, mice genetically engineered to be deficient
in glial fibrillary acidic protein (GFAP)-positive astro-
cytes have been generated by expressing herpes simplex
virus thymidine kinase from a mouse GFAP promoter.
Subsequent treatment for 1 week with Ganciclovir then
ablates all transgene-expressing, GFAP-positive astro-
cytes from the injured CNS (Bush et al., 1998). When
subjected to forebrain penetrating stab injury and subse-
quent ablation of GFAP positive astrocytes, these mice
show prolonged leukocyte infiltration, failure of BBB
repair with associated brain edema, neuronal degenera-
tion, and increased outgrowth of nerves fibers compared
with injured WT mice (Bush et al., 1999). These data
implicate a protective role for reactive or activated as-
trocytes in the postinjury period.
Insulinlike growth factors (IGF) I and II are peptides
related to the hormone insulin. They are present in serum
and tissue and are usually bound to IGF binding proteins
(IGFBP), which can increase or inhibit IGF action. In the
CNS, IGF-1 receptors are present in neurons, astrocytes,
and oligodendrocytes during development (Garcia-
Segura et al., 1991). In adult life, IGF-1 expression in
astrocytes is reactivated in response to injury (Garcia-
Estrada et al., 1992). To generate transgenic mice over-
expressing IGFBP-1, the entire coding region of the rat
IGFBP-1 gene was inserted downstream of the mouse
phosphoglycerate kinase (PGK-I) promoter. The IGFBP-
1/PGK-I fragment then was inserted into fertilized
C57BL/6JXCBA/JF1 zygotes. These IGFBP-1 overex-
pressing mice are characterized by reduced body weight,
hyperglycemia, and reduced brain size (Rajkumar et al.,
1995). To clarify the potential role of IGF-1 in activating
astrocytes during the postinjury process, a knife lesion
was stereotaxically placed in the right cerebral hemi-
sphere in both WT and transgenic mice overexpressing
IGFBP-1. The response of astrocytes to the injury was
reduced in the TG mice, suggesting an IGF-1–mediated
astrocyte response to this type of injury (Ni et al., 1997).
Matrix metalloproteinases
Gelatinase (MMP 9), a member of the metalloprotein-
ase family, is not constitutively expressed in the brain but
is induced after cerebral ischemia and trauma (Wang et
al., 2000; Sharp et al., 2000). After CCI brain injury in
C57BL/6 mice, MMP 9 levels increase by 3 hours after
injury and remain elevated for at least 1 week (Wang et
al., 2000). To evaluate the role of MMP 9 in brain injury,
MMP 9 knockout mice were generated by replacing part
of the gene with a cassette containing the neomycin
phosphotransferase cDNA (neor) driven by the PGK pro-
moter. Matrix metalloproteinase 9 (−/−) mice exhibit an
abnormal pattern of skeletal growth plate vascularization
and ossification in the long bones and show a lower
motor endurance compared with WT mice (Vu et al.,
1998). Matrix metalloproteinases 9 (−/−) mice subjected
to CCI brain injury show decreased motor deficits and
smaller lesion volumes compared with brain-injured WT
mice, suggesting that MMP 9 may play a deleterious role
during the secondary cascade after trauma (Fig. 2)
(Wang et al., 2000). Additional work is necessary to
confirm whether MMP 9 may be a future target for phar-
macologic intervention after TBI.
Nitric oxide
Nitric oxide (NO) has been suggested to play a role in
damage, recovery, or both after brain injury (Huang et
al., 1994; Mesenge et al., 1996; Holscher, 1997). Three
different systems are reportedly involved in NO synthe-
sis. Nitric oxide production by endothelial NO synthase
(eNOS) appears to provide beneficial effects in models
of TBI by preventing blood flow reduction (DeWitt et
al., 1997), whereas neuronal NOS (nNOS)-related NO
production has been suggested to exacerbate neuronal
damage in models of cerebral ischemia (Huang et al.,
1994). The final pathway involves inducible NOS
(iNOS) which is activated in response to inflammation
after experimental TBI with marked increases in expres-
sion 24 and 48 hours after injury (Clark et al., 1996).
To clarify the beneficial or detrimental effects of
iNOS-related NO production, mice deficient in iNOS
have been produced by targeted disruption of both the
iNOS promoter and the iNOS gene (MacMicking et al.,
1995). These homozygous knockout mice are healthy
and perform normally on motor and spatial memory ac-
quisition tasks when compared with WT mice. However,
mice deficient in iNOS showed greater latencies, com-
pared with WT littermates, to find a submerged platform
15 to 18 days after CCI brain injury, indicating impaired
learning performance in this strain and suggesting a pro-
tective role of iNOS, although the exact mechanism re-
mains unclear (Sinz et al., 1999). In the same study, the
protective role of iNOS was confirmed in a rat model of
CCI brain injury; administration of iNOS inhibitors ami-
noguanidine and L-N-iminoethyl-lysine resulted in re-
duced learning capacity and greater hippocampal cells
loss at 3 weeks after injury. Because these data are con-
trary to those obtained in the acute posttraumatic period
using the NO inhibitor aminoguanidine after lateral fluid
percussion (FP) brain injury in rats (Wada et al., 1998),
iNOS activity may exert detrimental effects in the acute
postinjury period but show beneficial effects in the
chronic phase. Further studies with knockout mice at
different time points are warranted to clarify the role of
NO after TBI. Figure 3 summarizes the main pathways
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related to the posttraumatic inflammatory response in-
vestigated using genetically engineered mice. Table 1
summarizes the results of the studies previously de-
scribed in the text with the main findings in relation to
the genotype used and the model of injury.
OXIDATIVE DAMAGE
The formation of reactive oxygen species (ROS) is
one of several major events in a biochemical cascade
leading to delayed neuronal death after TBI. Oxygen free
radicals are responsible for peroxidative damage to the
cell membrane, oxidation of proteins, and DNA leading
to cell damage and death through apoptotic and necrotic
pathways (Shohami et al., 1997a; Love, 1999). Under
physiologic conditions, ROS are continunously produced
during cellular respiration and are subsequently removed
by endogenous scavengers including superoxide dismu-
tases (SOD), glutathione peroxidase, and catalase. Su-
peroxide dismutase includes three isoforms: copper zinc
FIG. 2. (A) Representative Nissl-stained brain sections at 7 days after controlled cortical impact brain injury. (B) Matrix metalloprotein-
ase-9 knockout (KO) mice show smaller lesion volume compared with their wild type (WT) littermates (in cubic millimeters; mean ± SEM;
*P < 0.05). Reprinted with permission from Wang et al., 2000. Copyright ©2001 The Society of Neuroscience.
FIG. 3. Overview of the main pathways
involved in the posttraumatic inflamma-
tory cascade investigated using geneti-
cally engineered mice. ICAM, inter-
cellular adhesion molecules; ICE, In-
terleukin-1 converting enzyme; iNOS,
inducible nitric oxide synthase; LT, lym-
photoxin; MnSOD, manganese super-
oxide dismutase; ROS, reactive
oxygen species; TNF, tumor necrosis
factor.
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(CuZn)-SOD in the cytosol, MnSOD in mitochondria,
and high molecular weight extracellular (E)-SOD (Chan
et al., 1995; Love, 1999).
Transgenic CuZn-SOD overexpressing mice have
been generated through insertion of the human CuZn-
SOD 14.5 Kb gene, which includes the promoter se-
quence. These mice express 3- to 10-fold greater than
normal values of CuZn-SOD in the CNS and other tis-
sues (Shi et al., 1994). Typically, no phenotypic differ-
ences are observed between these mice and their WT
littermates, although some investigators have reported
certain morphologic abnormalities of the neuromuscular
junction in the tongue muscle (Avraham et al., 1988).
Studies involving cold (freeze lesion) injury or weight
drop brain injury have demonstrated that BBB perme-
ability, brain edema, and lesion volume are significantly
reduced and neurologic deficits are attenuated in CuZn-
SOD TG mice (Chan et al., 1991; Mikawa et al., 1996;
Murakami et al., 1999).
Manganese superoxide dismutase overexpressing
mice have been generated by inserting the human
MnSOD gene through microinjection into the pronuclei
of mouse fertilized eggs. Overexpression of MnSOD in
transgenic mice is associated with smaller cortical con-
tusion volume 7 days after CCI brain injury compared
with brain-injured WT controls (Sullivan et al., 1999).
Although the results of these laboratory studies using TG
mice have been replicated using pharmacologic treat-
ment to inhibit ROS in the experimental setting, clinical
trials with the free radical scavenger polyethylene gly-
col–conjugated SOD or tirilazad mesylate, a 21-
aminosteroid inhibitor of free radical–mediated lipid per-
oxidation, have not yet produced significant benefits in
patients with head injuries (Young et al., 1996; Marshall
et al., 1998).
DNA DAMAGE AND REPAIR
Clinical and experimental TBI are characterized by
progressive cell death. Two morphologic phenotypes of
cell death have been described: necrotic and apoptotic.
Both share DNA fragmentation, detectable by the (TdT)-
mediated deoxyuridine triphosphate (dUTP) nick end la-
beling (TUNEL) technique (Gavrieli et al., 1992). Be-
cause morphologic features of necrosis and apoptosis
have been documented in the same neural cells, it has
been hypothesized that a continuum exists between ap-
optosis and necrosis (Portera-Cailliau et al., 1997). The
intracellular pathways leading to these two forms of cell
death may coexist and/or overlap sequentially, and the
prevalence of apoptotic or necrotic features at any single
time may be related to the intensity of the insult, energy
production by the mitochondria, intracellular level of cal-
cium, and reparative mechanisms (Raghupathi et al.,
2000).
TABLE 1. Summary of studies performed with genetically engineered mice to investigate specific molecules involved in the
inflammatory posttraumatic response
Genotype
Model of
injury
Behavioral
outcome*
Histologic
outcome*
Main result of
the study† Reference Vendor‡
ICAM-1 (−/−) CCI Unaffected Unaffected Equal brain neutrophil
accumulation
Whalen, 1999a Jackson
ICAM-1/P-selectin
(−/−)
CCI Unaffected Unaffected ↓ brain edema Whalen, 2000 Jackson
TNF (−/−) CCI Acute phase: improved
Chronic phase:
worsened
Worsened Biphasic trend in outcome Scherbel, 1999 Jackson
TNF/lymphotoxin
(−/−)
WD Unaffected Unaffected ↑ mortality Stahel, 2000 NA
TNF receptor (−/−) CCI NA Worsened ↑ lesion volume
↑ edema
Sullivan, 1999 NA
Caspase-1 (−/−) CCI Improved Improved ↓ lesion volume Fink, 1999 NA
IL-6 (−/−) CFI NA Worsened ↑ neuronal loss Penkowa, 1999b Jackson
MT I-II (−/−) CFI NA Worsened Abnormal
Inflammatory response
Penkowa, 1999a
Penkowa, 2000
Jackson
C57BL/6 WldS CCI Delayed effects of injury Fox, 1998 Jackson
GFAP-positive
astrocytes deletion
Stab injury NA Worsened ↑ edema failure in repair
neuronal degeneration
Bush, 1999 Jackson
IGFBP
overexpressing
Dissecting lesion NA NA Reduce astrocyte activation Ni, 1997 NA
MMP 9 (−/−) CCI Improved Improved ↓ lesion volume Wang, 2000 NA
iNOS (−/−) CCI Worsened NA ↑ cognitive deficit Sinz, 1999 Jackson
ICAM-1, intercellular adhesion molecule 1; CCI, controlled cortical impact; TNF-, tumor necrosis factor-; WD, weight drop; CFI, cortical freeze
injury; GFAP, glial fibrillary acidic protein; IGFBP, insulinlike growth factor binding proteins; MMP 9, gelatinase; iNOS, inducible nitric oxide
synthase; NA, not applicable.
* Results of genetic manipulation on the response to traumatic brain injury (TBI) compared with the response of their related wild type (WT)
littermates.
† Description of the main effect of TBI in genetically engineered mice compared with related WT littermates.
‡ Source where these genetically modified mice are commercially available.
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As previously described, ROS that are released after
TBI can induce DNA strand breaks (Love, 1999). The
tumor suppressor gene p53 is up-regulated after DNA
damage and can lead to DNA repair, cell growth arrest,
or apoptosis (Evan and Littlewood, 1998). Napieralski et
al. (1999) reported that p53 mRNA is up-regulated after
lateral FP brain injury in rats, suggesting that p53 may
play a role in the molecular response to TBI leading to
cell death. To further evaluate the role of p53 after TBI,
p53 knockout mice were generated through homologous
recombination using a target vector containing 3.7 kilo-
bases of the genomic p53 gene, interrupted in exon 5 by
a PolII-neo expression cassette. Mice deficient in p53
appear healthy at birth but are prone to the spontaneous
development of neoplasms by 6 months of age (Done-
hower et al., 1992). Because mice deficient in p53 show
less histologic damage in models of excitotoxicity (sub-
cutaneous kainic acid injection) and focal ischemia
(middle cerebral artery occlusion) (Crumrine et al., 1994;
Morrison et al., 1996), Tomasevic et al. (1999) compared
the effects of CCI brain injury in p53 knockout mice and
their WT littermates. At 7 days after injury, p53 (−/−)
mice exhibited attenuated motor function deficits com-
pared with their WT littermates, but no differences were
found in cortical lesion volume or cell loss in the hippo-
campus and thalamus between WT and p53-deficient
mice. These results may be explained, in part, by the fact
that DNA damage-induced up-regulation of p53 gene
may activate different pathways, such as induction of the
proapoptotic bax gene family, leading to cell death (Mi-
yashita and Reed, 1995), or induction of the wild type
p53-activated fragment (WAF/p21) and the growth arrest
and DNA damage-inducible gene GADD45, leading to
cell survival (Artuso et al., 1995).
Poly (ADP-ribose) polymerase (PARP) is a nuclear
enzyme that has been proposed to play a role in the repair
of DNA damage. Normally, DNA strand breaks activate
PARP, which then binds to the nicked DNA and uses
NAD+ as a substrate to form Poly (ADP-ribose) (PAR).
This process continues until a critical PAR chain length
is reached and then PARP is released from DNA and
other repair enzymes complete the repair process. Al-
though lateral FP brain injury in the rat initially activates
PARP by 30 minutes after injury, evidence suggests that
the PARP molecule is subsequently degraded by
caspase-3–mediated cleavage, leading to significant
DNA fragmentation (LaPlaca et al., 1999). However, it
has been hypothesized that excessive activation of PARP
also may lead to consumption of NAD, ATP reduction,
cell dysfunction, and death associated with energy failure
(Berger, 1985). Poly (ADP-ribose) polymerase (−/−)
mice, produced by deleting part of exon 2, develop nor-
mally and are fertile. Analysis of tissues isolated from
these mice confirmed absence of PARP activity, but re-
vealed that these mice are able to repair DNA damage
induced by UV and alkylating agents (Wang et al.,
1995). Genetically engineered mice deficient in PARP
show attenuated functional deficits but equivalent histo-
logic outcome after CCI brain injury, suggestive of a
protective mechanism through the inhibition of posttrau-
matic energy failure (Whalen et al., 1999b). Further stud-
ies are warranted to elucidate the mechanisms underlying
these results and to evaluate whether pharmacologic in-
hibition of PARP might represent a therapeutic strategy
for reducing neurologic injury after TBI, as recently
shown by LaPlaca et al. (2001) in a model of lateral
FP brain injury in rats. Figure 4 summarizes the path-
ways related to oxidative brain damage and DNA dam-
FIG. 4. Overview of the pathways involved in the oxidative brain damage, physiologic endogenous scavenger, and DNA damage- and
repair-related mechanisms evaluated using genetically engineered mice. NO, nitric oxide; CuZn SOD, copper zinc superoxide dismutase;
MnSOD, manganese superoxide dismutase; PARP, poly (ADP-ribose) polymerase; TBI, traumatic brain injury.
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age investigated, to date, using genetically engineered
mice.
APOPTOSIS
Apoptotic cell death has been reported to occur in the
acute and the chronic posttraumatic period after lateral
FP and CCI brain injury in rats and more recently in
tissue from patients with head injuries (Rink et al., 1995;
Colicos and Dash, 1996; Conti et al., 1998; Newcomb et
al., 1999; Smith et al., 2000). Apoptosis is triggered by
intracellular or extracellular signals that converge to ac-
tivate a specific group of cysteine proteases called
caspases. Caspase activation occurs through 2 different
pathways. The first (extrinsic) pathway involves TNF-
and Fas receptors at the cell surface leading to activation
of caspase-8, which then activates downstream caspases
such as caspase-3, -6, and -7. The second (intrinsic) path-
way involves the release of cytochrome c from the mi-
tochondria. It is generally believed that cytochrome c
binds to Apaf-1 and this complex recruits and activates
procaspase-9, which finally activates the downstream
caspases-3, -6, and -7 (Hengartner, 2000; Yuan and
Yankner, 2000).
Apoptosis is controlled by the bcl-2 family of genes
including proapoptotic factors such as bak, bim, bad, and
bax and antiapoptotic factors bcl-2 and bcl-xl, whose
activity is related to cytochrome c and caspase activation.
An imbalance in the expression of one of these groups of
genes may exacerbate or reduce the extent of cell death
after neuronal injury (Graham et al., 2000b). The bcl-2
gene family may play an important role in controlling
cell survival after CNS injury, and an increase in bcl-2
mRNA and bcl-2 protein has been observed after experi-
mental and clinical TBI (Clark et al., 1997, 1999, 2000).
In contrast, Raghupathi et al. (unpublished data, 2000)
recently evaluated the ratio between proapoptotic and
antiapoptotic members of the bcl-2 family and observed
that bcl-2 immunoreactivity was decreased in the injured
cortex and injured hippocampus by 2 hours after lateral
FP injury. At 24 hours after injury, the authors also ob-
served an increase in bax mRNA and proteins in the
perilesion area. These data suggest that the resulting
changes in the bax/bcl-2 ratio could participate in the
posttraumatic pattern of apoptosis in the injured cortex
and hippocampus.
Mice overexpressing human bcl-2 have been gener-
ated by transfecting the human bcl-2 gene under the con-
trol of synapsin I promoter fragment. Raghupathi et al.
(1998) subjected these bcl-2 overexpressing mice to CCI
brain injury, then compared them with WT littermates.
Transgenic mice overexpressing bcl-2 demonstrated in-
creased human bcl-2 expression in the cortex, hippocam-
pus, and midbrain and reduced cortical lesion volume by
1 week after injury when compared with WT littermates.
Surprisingly, no differences in neurologic motor function
were observed between transgenic and WT mice. Naka-
mura et al. (1999a) studied mice overexpressing human
bcl-2 controlled by the neurofilament light-chain pro-
moter. These mice (overexpressing human bcl-2 protein
in the cortex, hippocampus, and thalamus) were sub-
jected to CCI brain injury and then were compared with
their WT littermates. Human bcl-2 overexpression was
associated with smaller cortical lesion volume and hip-
pocampal cell loss, confirming a protective role of the
bcl-2 protein. Despite histologic protection, TG mice
were as impaired as their WT littermates with respect to
posttraumatic cognitive function.
Several mechanisms can explain a protective role for
bcl-2, including the capacity to reduce ROS generation,
an increased capacity to buffer posttraumatic intracellu-
lar calcium increases, and the blockade of cytochrome c
release from the mitochondria preventing subsequent ac-
tivation of caspases. Recently, the protective effect of
bcl-2 was confirmed by the manipulation of its expres-
sion in a rat model of middle cerebral artery occlusion
with the use of antisense oligodeoxynucleotides, which
suppressed endogenous expression and exacerbated isch-
emic neuronal death (Chen et al., 2000).
Among the proapoptotic factors of the bcl-2 family of
genes, bax has been shown to induce apoptosis by acti-
vating caspase-3 (Cregan et al., 1999). After CCI brain
injury in rats, a translocation of bax into the nuclei of
neurons destined to die of apoptosis was observed at 48
hours postinjury (Kaya et al., 1999). Knockout of the bax
gene has been produced in bax (−/−) mice by homolo-
gous recombination substituting exons 2, 4, and part of 5
with a target vector (PGK-Neo). These mice are viable
and show thymocyte hyperplasia and infertility in the
males. In addition, the knockout of bax leads to a reduc-
tion in the magnitude of naturally occurring programmed
cell death in sympathetic and facial motor neurons
(Knudson et al., 1995). Cultures of neurons from bax
(−/−) mice are resistant to excitoxicity produced by ad-
ministration of glutamate or kainate and DNA damage
induced by camptothecin, suggesting that bax is involved
in different pathways of cell death (Xiang et al., 1998).
Carbonell et al. (1999) tested the hypothesis that this
proapoptotic factor is involved in the acute cortical and
hippocampal damage after lateral FP brain injury by
comparing the response of bax (−/−) mice and their WT
littermates to TBI. As early as 10 minutes after lateral FP
brain injury, bax (−/−) mice showed fewer damaged neu-
rons than the WT-injured mice in the hippocampus but
not in the cortex, suggesting that bax is involved in me-
diating acute posttraumatic hippocampal neuronal dam-
age. Because the hippocampus contains a high concen-
tration of excitatory amino acid receptors, these results
might be explained by an increased resistance to excito-
toxicity caused by the suppression of bax.
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Downstream from caspase activation, DNA fragmen-
tation is mediated by a heterodimeric protein composed
of 40- and 45-kDa subunits. These subunits have been
named DNA fragmentation factor (DFF)-40 (or caspase
activated DNAase (CAD)) and DFF-45 (or inhibitor of
CAD, ICAD). During apoptosis, caspase-3 is believed to
cleave DFF-45, dissociating it from DFF-40 and induc-
ing a transformation of DFF-40 into a large protein com-
plex with DNAase activity. The proteolytic activity of
DFF-40 requires DFF-45 to be reactivated, suggesting
that DFF-45 is a chaperone molecule that is essential for
DFF-40 synthesis and activation (Liu et al., 1997, 1998;
Enari et al., 1998). Regional changes of DFF-40 and 45
have been documented in lateral FP brain injury, where
a decrease in DFF-45–like proteins in rat cortex was
observed in the cytosolic and nuclear fraction during the
first 24 hours after injury (Zhang et al., 1999). In the
hippocampus, DFF-40 was found to be reduced in the
cytosolic fraction and increased in the nuclear fraction at
2 and 24 hours after brain injury, suggesting that a trans-
location from cytoplasm to nucleus occurs during post-
traumatic apoptosis (Zhang et al., 1999).
The generation of DFF-45 mutant mice has been
achieved through the deletion of 1–3 exons through ho-
mologous recombination (Zhang et al., 1998). DFF-45
(−/−) mice contain normal levels of DFF-40 (which is
not functional) and caspase-3, are healthy and fertile, and
grow without obvious abnormalities. No spontaneous
DNA fragmentation has been observed in neurons iso-
lated from these mice. Moreover, cells isolated from the
spleen and thymus are resistant to DNA fragmentation
and chromatin condensation in response to apoptotic
stimuli, suggesting that DFF-45 plays a critical role dur-
ing apoptosis (Zhang et al., 1998). These DFF 45 (−/−)
mice were found to have a smaller lesion volume than
WT mice at 1 and 4 days after CCI brain injury, sug-
gesting a neuroprotective role of DFF 45 deletion in the
acute posttraumatic period (Zhang et al., 2000).
Despite the progress that has been made during the
past few years in understanding the molecular mecha-
nisms associated with posttraumatic cell death, the com-
plexity of these pathways and whether apoptosis also
may have a beneficial or protective role—by which the
brain removes injured cells with minimal damage to sur-
rounding tissue—in the setting of CNS injury remains
unclear. Further investigations with genetically engi-
neered mice are warranted to clarify the potential targets
for a rational approach to the design of new pharmaco-
logic therapies to prevent this type of cell death. Figure
5 summarizes the apoptotic pathways investigated with
genetically engineered mice. Table 2 summarizes the re-
sults of the studies related to oxidative damage, DNA
damage, repair, and apoptosis described in the text with
the main findings in relation to the genotype used and the
model of injury.
TRAUMATIC BRAIN INJURY
AND NEURODEGENERATION
Alzheimer disease
Although TBI is a known epidemiologic risk factor
for Alzheimer disease (AD), the mechanistic link is not
yet fully understood (Plassman et al., 2000). After a
single severe head injury or a series of repetitive mild
head injuries (in boxers), a cohort of TBI patients share
many pathologic features with patients suffering from
FIG. 5. Extrinsic and intrinsic pathways
of apoptosis and molecules investi-
gated using genetically engineered
mice after traumatic brain injury. DFF,
DNA fragmentation factor; TNF, tumor
necrosis factor.
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AD—including deposition of plaques containing -amy-
loid (A) derived from the proteolysis of amyloid pre-
cursor protein (APP) and composed of fibrils formed by
39–43 amino acid peptides, and the presence of neuro-
fibrillary tangles in which paired helical filaments are
composed of abnormally phosphorylated tau (Tokuda et
al., 1991; Roberts et al., 1994). Alzheimer disease is
believed to be profoundly influenced by genotype. In
kindreds of familial AD patients, mutations are known to
occur in genes encoding for APP and presenilin 1 and 2,
which result in an increase in the A peptides levels
(Borchelt et al., 1998). Moreover, genetic studies have
found a correlation between the common form of AD
and the allele  4 of the apolipoprotein E (APOE) gene on
chromosome 19 (Strittmatter et al., 1993). Recently, pa-
tients expressing the  4 allele of apoE have been re-
ported to have an increased vulnerability and worse out-
come after brain trauma (Teasdale et al., 1997; Lichtman
et al., 2000). Because head injury is epidemiologically
linked to AD, this relation recently has been studied in
experimental transgenic mouse models to reveal novel
and relevant pathogenetic mechanisms.
Amyloid precursor protein
Amyloid precursor protein is subjected to proteolytic
degradation leading to generation and secretion of the
A peptide. Approximately 90% of secreted -amyloid
peptide is in the form of A1–40 and 10% are A1-(42–
43). The A1-(42–43) contains amino acids that are
highly fibrillogenic, readily aggregated, and deposited
early and selectively in amyloid plaques (Borchelt et al.,
1998). Traumatic brain injury in humans and rodents
induces accumulation of APP in perikarya of neurons
and in damaged axons (Pierce et al., 1996; Bramlett et
al., 1997; Sheriff et al., 1994). Despite this increase in
APP, experimental models of TBI in rodents currently
have not been associated with A-plaque development,
probably because of differences in amino acid composi-
tion between different species (Pierce et al., 1996).
Transgenic yeast artificial chromosome (YAC) mice
have been generated by introducing the human APP gene
into embryonic stem cells (lipofection of a 650-Kb YAC
containing the APP gene). The CNS of these APP-YAC
mice overexpresses APP twofold when compared with
normal mice (Pearson and Choi, 1993). Murai et al.
(1998) subjected APP-YAC mice to CCI brain injury and
failed to observe any differences in posttraumatic cogni-
tive function, neurologic motor deficits, APP expression,
reactive astrocytosis, or cell loss between brain-injured
TG mice and injured WT littermates. Moreover, no AD-
like plaque deposition was observed in either brain-
injured WT or APP overexpressing mice.
A second strain of mice that has been used in TBI
research overexpresses a mutant APP minigene (contain-
ing the familial AD mutation Phe for Val in position 717)
driven by a platelet-derived growth factor promoter
(PDAPP). These mice overexpress mutant APP 10-fold
when compared with normal mouse APP and develop
plaques at 6 months of age (Games et al., 1995). Naïve
(uninjured) PDAPP mice exhibit impaired memory func-
tion when compared with their WT littermates. However,
CCI brain injury exacerbated these cognitive impair-
ments and produced a concomitant increase in hippo-
campal A1–40 and 1–42 that was associated with a near
complete cell loss (>80%) in the CA3 region in the in-
jured hemisphere (Smith et al., 1998). This study led the
authors to develop a “two-hit hypothesis,” whereby a
first “hit” or insult is represented by genetic vulnerability
(that is, high concentration of amyloidogenic species of
A) that becomes manifest only after a second epige-
netic insult or “hit” such as TBI. The resulting increase in
cell loss may depend on the combination of direct neu-
rotoxic activity of -amyloid protein, abnormalities of
TABLE 2. Summary of studies performed with genetically engineered mice to investigate the pathways related to posttraumatic
oxidative damage, DNA damage/repair, and apoptosis
Genotype
Model of
injury
Behavioral
outcome*
Histologic
outcome*
Main result of
the study† Reference Vendor‡
CuZn SOD overexpressing CFI NA Improved ↓ edema and infarction Chan, 1991 Jackson
CuZn SOD overexpressing WD Improved Improved ↓ edema and lesion volume Mikawa, 1996 Jackson
CuZn SOD overexpressing CFI NA Improved ↓ edema Murakami, 1999 Jackson
Mn-SOD overexpressing CCI NA Improved ↓ lesion volume Sullivan, 1999 NA
p53 (−/−) CCI Improved Unaffected Same histologic damage Tomasevic, 1999 NA
PARP (−/−) CCI Improved Unaffected ↑ functional outcome Whalen, 1999 NA
Bcl-2 overexpressing CCI Unaffected Improved ↓ lesion volume Raghupathi, 1998 Jackson
Bcl-2 overexpressing CCI Unaffected Improved ↓ lesion volume and hippocampal cell loss Nakamura, 1999 Jackson
Bax (−/−) LFP NA Improved ↓ hippocampal cell loss Carbonnell, 1999 Jackson
DFF 45 (−/−) CCI NA Improved ↓ lesion volume Zhang, 2000 NA
CuZn SOD, copper zinc superoxide dismutase; CCI, controlled cortical impact; WD, weight drop; CFI, cortical freeze injury; PARP, Poly
(ADP-ribose) polymerase; LFP, lateral fluid percussion; DFF, DNA fragmentation factor; NA, not applicable.
* Results of genetic manipulation on the response to traumatic brain injury (TBI) compared with the response of their related wild type (WT)
littermates.
† Description of the main effect of TBI in genetically engineered mice, compared with related WT littermates.
‡ Source where these genetically modified mice are commercially available.
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the endosomal-lysosomal system, excitoxicity, activation
of proteases, and/or apoptotic pathways (Borchelt et al.,
1998). Using the identical strain of PDAPP mice, Nak-
agawa et al. (1999) observed that CCI brain injury at the
same age (4 months) actually reduced plaque deposition
with time (follow up at 2, 5, and 8 months after TBI).
These authors hypothesized that this reduction in A
plaques may depend on decreased secretion of A as a
consequence of cell death observed in hippocampus and
cingulate cortex, resulting from the combination of the
previously described two insults. Subsequently, Nak-
agawa et al. (2000) subjected 2-year-old PDAPP mice to
CCI brain injury. By 16 weeks after injury, brain-injured
aged transgenic mice showed a remarkable decrease in
A deposits in the ipsilateral atrophic hippocampus, re-
flecting the massive hippocampal neuronal loss in these
mice. The widespread neuronal cell loss associated with
the moderate severity CCI brain injury may have offset
the A production preventing plaques formation.
Laurer et al. (personal communication) have recently
investigated the effect of repetitive mild brain injury in a
different strain of mutant APP TG mice. These mice
express a human APP gene containing the double muta-
tion Lys670 → Asn and Met671 → Leu, found in a large
Swedish family with the early onset of AD (Hsiao et al.,
1996). The hallmark of these TG mice is the association
of elevated concentrations of A, plaque formation, and
neurobehavioral impairment beginning at 9 to 10 months
of age (Hsiao et al., 1996). These TG mice had preinjury
learning deficits by 7 months of age compared with WT
littermates. A single episode of concussive brain injury,
induced before plaque development, led to an acute cog-
nitive impairment but failed to exacerbate histologic
damage in this strain. However, repetitive, mild head
injury induced both delayed cognitive alteration and bi-
lateral increases in plaque deposition, suggesting that
mild repetitive head injury may be a risk factor associ-
ated with an accelerated neurodegenerative process in a
genetically vulnerable population (Laurer, personal com-
munication). The results of this study encourage further
evaluation of selectively vulnerable genotypes exposed
to repetitive mild head injury.
Apolipoprotein E
In humans, apoE is a polymorphic protein (E2, E3, E4)
in which isoforms differ from each other by 1 amino acid
(Mahley, 1988). Recent epidemiologic studies have iden-
tified the 4 allele of apoE as a major risk factor for
sporadic and late-onset familial AD (Strittmatter et al.,
1993). Apolipoprotein E is an important apolipoprotein
constituent of cerebrospinal fluid and brain, where it is
produced by glial cells. This specific apolipoprotein is
involved in nervous system growth and repair through
the coordination of the mobilization and redistribution of
cholesterol during neuronal development. However, pa-
tients carrying apoE4 genotype have been reported to
show a poorer outcome after TBI (Teasdale et al., 1997;
Lichtman et al., 2000).
Genetically engineered mice have been produced and
used to clarify the mechanisms by which this genotype
influences posttraumatic brain damage. It has been hy-
pothesized that apoE4 induces a loss of function of the
E3 isoform; therefore, the biologic abnormalities during
aging or after injury associated with the apoE4 genotype
should be evident in apoE knockout mice. The deletion
of the APOE gene has been achieved by replacing exon
2 of the APOE gene with a neomycin resistance gene.
Apolipoprotein E (−/−) mice appear healthy at 4 to 6
weeks of age and do not have abnormalities in the septo-
hippocampal system (Piedrahita et al., 1992). Homozy-
gous apoE- deficient mice subjected to enthorinal cortex
lesions exhibited persistent degeneration products (cho-
lesterol-derived) in the deafferented hippocampus, com-
pared with WT mice, suggesting that apoE may play a
role in the clearance of cholesterol-laden neurodegenera-
tion products after injury (Fagan et al., 1998). Moreover,
apoE knockout mice subjected to weight drop brain in-
jury showed significantly exacerbated memory impair-
ment and motor deficits when compared with brain-
injured WT controls for at least 40 days (Chen et al.,
1997). Histopathologic examination revealed overt neu-
ronal cell death bilaterally in the hippocampus of the
injured apoE (−/−) mice. One possible explanation for
the enhanced vulnerability of apoE (−/−) mice to TBI is
the partial loss of oxidative homeostasis causing an in-
crease in lipid peroxidation products, chronic oxidative
stress, and reduction in low molecular weight antioxi-
dants (Lomnitski et al., 1999).
One of the additional pathologic features of AD is the
presence of neurofibrillary tangles composed of hyper-
phosphorylated tau, leading to cytoskeletal abnormalities
that contribute to neuronal degeneration. Apolipoprotein
E (−/−) mice typically show increased tau phosphoryla-
tion compared with WT mice. After weight drop brain
injury, a transient increase in tau hyperphosphorylation
has been observed in WT and apoE (−/−) mice, although
the extent and time course in the two mouse groups
varied markedly (Genis et al., 2000). In brain-injured
WT mice, hyperphosphorylation was maximal by 4
hours after injury and reverted to basal levels by 24
hours, whereas brain-injured apoE (−/−) mice showed
hyperphosphorylation of “hot spot” epitopes of the tau
protein for a longer duration after TBI, even if it was
reduced in its extent (Genis et al., 2000). The authors
suggest that the greater hyperphosphorylation of these
“hot spot” epitopes of tau protein might reflect repair
mechanisms associated with an acute insult such as TBI.
Although the exact pathogenic link between apoE, TBI,
and AD is unclear, these studies reveal that apoE geno-
type may be related to the maintenance of oxidative ho-
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meostasis and repair mechanisms after injury to the CNS.
Further studies with genetically engineered animals are
warranted to help clarify the link between TBI, apoE
genotype, and Alzheimer disease.
OTHER NEURODEGENERATIVE DISEASES
LINKED TO TBI
Several neurodegenerative diseases including Parkin-
son disease, diffuse Lewy-body dementia, and fronto-
temporal dementia with Parkinsonism are characterized
by intracellular neurofilament (NF)-rich filamentous in-
clusions in neurons. Tau protein and -synuclein are the
major building block proteins of neurofibrillary tangles
and Lewy bodies, respectively, which are observed in
several neurodegenerative diseases (tauopathies and
synucleinopathies). These disorders share many patho-
genic mechanisms and may cause neuronal toxicity
through common pathways (Lee et al., 2001; Tro-
janowski and Lee, 2001). Because TBI can cause or ac-
celerate latent and progressive neurodegenerative events,
it appears reasonable to investigate this relation in trans-
genic animals showing NF inclusions.
Transgenic mice expressing a construct composed of
the mouse polypeptide NF-heavy (NFH) subunit linked
to the LacZ gene (NFH/LacZ) develop NF-rich inclu-
sions in virtually all neurons of the CNS. The phenotypic
features of these mice—such as tremor, ataxia, and mus-
cular weakness—become evident by 1 year (Tu et al.,
1997). Nakamura et al. (1999b) subjected NFH/LacZ
mice to CCI brain injury before the onset of behavioral
signs and observed a significant and prolonged deficit in
motor function up to 3 weeks after injury that was asso-
ciated with increased lesion volume when compared with
brain-injured WT mice. A subsequent study comparing
the histologic damage between NFH/LacZ and WT
brain-injured mice revealed a greater lesion cavity, in-
creased apoptotic cell death, more pronounced hippo-
campal cell loss in the CA3 region and dentate gyrus,
increased reactive gliosis, and greater cytoskeletal dam-
age, as assessed by changes in immunoreactivity for
MAP2, beta tubulin, and synaptophysin in NFH/LacZ
mice (Galvin et al., 2000). Intracellular NF-rich inclu-
sions may lead to increased vulnerability caused by al-
terations in axonal transport or impaired function of in-
tracellular organelles entrapped in the inclusions.
Taken together, these studies suggest that TBI may be
a strong risk factor for neurodegenerative disorders. It
appears likely that genetic factors—such as mutations in
genes for APP, presenilins, APOE4 genotype, or in genes
encoding for cytoskeletal proteins—may confer a vul-
nerability that becomes evident after exposure to epige-
netic insults. Figure 6 summarizes the relevant pathoge-
netic mechanisms related to the epidemiologic link be-
tween TBI and neurodegenerative diseases investigated
with genetically engineered mice. Table 3 summarizes
the results of the related studies described in the text with
the main findings in relation to the genotype used and the
model of injury.
FUTURE DIRECTIONS
Traumatic brain injury activates a prolonged patho-
physiologic cascade directly influencing the complex
network associated with neurodegeneration and
repair/regeneration pathways in the CNS. The need to
explore the molecular basis of cellular dysfunction and
death after injury to the CNS has led researchers to
transgenic technology. Genetically engineered animals,
obtained by artificial overexpression or deletion of a spe-
cific gene, offer the unique opportunity to test mecha-
nistic hypotheses concerning cause and effect relations
and to provide a mechanistic basis for the evaluation of
potentially effective therapeutic agents targeted at selec-
tive secondary pathways activated after TBI. When com-
pared with the use of pharmacologic agents to antagonize
or enhance specific pathways, this technology offers sev-
eral advantages, such as the possibility of overcoming
FIG. 6. Relation between traumatic
brain injury (TBI) and neurodegenera-
tive diseases. Relevant pathogenetic
mechanisms evaluated with genetically
engineered mice. apoE, apolipoprotein
E; APP, amyloid precursor protein;
NFH, neurofilament-heavy.
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obstacles related to optimal time window for treatment,
cerebral tissue penetration, sex differences in metabo-
lism, and toxicity. However, developmental compensa-
tory mechanisms caused by a chronic alteration of the
target gene may cause responses to TBI that are different
from those in the WT littermates in which a molecule-
mediated effect is blocked by a pharmacologic agent.
Additional caveats must be acknowledged with respect
to the use of genetically modified animals in TBI re-
search. Various strains of mice (C57BL/6, C57BL/10,
C57SJL, 129/SvEMS, FVB/N) have shown different and
highly specific cognitive, behavioral, and histologic out-
comes after excitotoxic cell death or the induction of
stroke or trauma (Steward et al., 1999). For example,
three background strains of mice (C57BL/6, FVB/N, and
129/SvEMS) have been reported to exhibit significantly
different behavioral responses when subjected to CCI
brain injury (Fox et al., 1999). These results suggest that
the background strain should be carefully considered
when experiments involve genetically altered mice, es-
pecially when the studies use behavioral outcome mea-
sures after CNS injury (Steward et al., 1999).
The polymorphism inherent in the genetic background
of genetically engineered mouse strains can potentially
make the result of gene-targeting studies difficult to in-
terpret. A phenotypic change observed in a mutant
mouse, therefore, may be related to the genetic back-
ground rather than the mutation itself. In fact, most gene
targeting is performed in embryonic stem cells derived
from strain 129/Sv. These cells are introduced into a
blastocyst, and the derived chimeric adult mice then are
mated to WT mice. If the WT mice are C57BL/6, the first
derived generation will be heterozygous for the mutant
allele but also will have a set of chromosomes derived
from 129/Sv and C57BL/6. The mating of these hetero-
zygous mice will produce a second generation composed
of homozygous mutant, heterozygous mutant, and WT,
all of whom have different loci for the targeted mutated
gene. Consequently, one associated risk of these studies
is the presence of false positive or negative results de-
pending on the genetic background itself and not on the
targeted mutation (Gerlai, 1996). Solutions for these po-
tential pitfalls include increasing the number of animals,
thereby increasing the power of statistical comparison
and reducing the possibility of sampling error associated
with differences among background strains, and care-
fully analyzing both genotype and phenotype of the ani-
mals to confirm that the phenotype maps consistently to
the genotype at the targeted locus (Steward et al., 1999).
In spite of these potential pitfalls, the successful pro-
duction of genetically modified mice lacking or overex-
pressing specific mediators and receptors has made it
possible to investigate the cellular and molecular role of
inflammation, ROS, DNA damage and repair, and cell
death mediators in TBI. Several inflammatory factors—
such as intercellular adhesion molecules, cytokines, and
their receptors—have been investigated using this new
technology, although many questions remain unresolved.
Degenerative and regenerative processes associated with
posttraumatic inflammation may represent a duality of
inflammatory processes, which interact in a complex
way during a prolonged posttraumatic time course. The
goal of antagonizing (or enhancing) a specific pathway
to obtain a therapeutic benefit therefore may be too sim-
plistic, because the same molecule may exert beneficial
(neuroprotective) or deleterious (neurotoxic) effects at
different time points in the postinjury cascade. More
work needs to be performed to clarify the role of specific
pathogenic cascades such as inflammation and apoptosis
in mediating cell death, to design targeted therapies that
can be sequentially combined in the acute and chronic
postinjury periods to reduce damage and stimulate re-
parative processes. Genetically engineered mice also
have stimulated the exploration of the molecular basis
underlying the relation between head injury and neuro-
degenerative diseases, including such diverse pathways
TABLE 3. Summary of studies performed to clarify the epidemiological relation between TBI and neurodegenerative diseases
Genotype
Model of
injury
Behavioral
outcome*
Histologic
outcome*
Main result of
the study† Reference Vendor‡
APP-YAC CCI Unaffected Unaffected No differences with WT Murai, 1998 NA
PDAPP CCI Worsened Worsened ↑ hippocampal cell loss Smith, 1998 NA
PDAPP CCI NA Worsened No A plaques Nakagawa, 1999, 2000 NA
APP Swe RHI Worsened Worsened ↑ A plaques Laurer (unpublished) NA
apoE (−/−) ECL NA Worsened Persistency of neuronal degeneration products Fagan, 1998 Jackson
apoE (−/−) WD Worsened Worsened No recovery Chen, 1997 Jackson
apoE (−/−) WD NA NA Prolonged tau hyperphosphorylation Genis, 2000 Jackson
NFH-LacZ CCI Worsened Worsened No functional recovery Nakamura, 1999 NA
NFH-LacZ CCI NA Worsened ↑ neuronal cell loss Galvin, 2000 NA
TBI, traumatic brain injury; APP, amyloid precursor protein; YAC, yeast artificial chromosome; CCI, controlled cortical impact; PDAPP,
platelet-derived growth factor promoter-APP; A plaques, those containing -amyloid; apoE, apolipoprotein E; WD, weight drop; RHI, repetitive
closed head injury; ECL, entorhinal cortex lesion; NA, not applicable; NFH, neurofilament-heavy.
* Results of genetic manipulation on the response to TBI compared with the response of their related wild type (WT) littermates.
† Description of the main effect of TBI in genetically engineered mice, compared with related WT littermates.
‡ Source where these genetically modified mice are commercially available.
L. LONGHI ET AL.1254
J Cereb Blood Flow Metab, Vol. 21, No. 11, 2001
as abnormalities in APP, -amyloid, apoE genotype, and
cytoskeletal proteins. Further studies are warranted to
help clarify how specific genotypes and the pathways
mentioned above may interact at different time points in
the postinjury period and to promote the evaluation of
new therapeutic strategies in well-characterized models
of TBI.
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